Filter By Category
Archives
Share on -
APLAVIROC
Generic Name: APLAVIROC
ABSTRACT -
Aplaviroc is an investigational CCR5 antagonist developed as an HIV-1 entry inhibitor.
It blocks CCR5-mediated viral entry in CCR5-tropic HIV strains.
Clinical development was discontinued after safety concerns, including liver toxicity signals.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved dosing regimen is established.
- Historical HIV clinical studies used oral protocol-defined dosing.
- It should not be used outside authorized research or specialist review.
SIDE EFFECTS–
- Possible side effects may include:
- Elevated liver enzymes
- Nausea
- Diarrhea
- Headache
- Fatigue
- Rash
- Abdominal discomfort
- Potential severe hepatotoxicity
ALLERGIC REACTIONS -
- Hypersensitivity to the active compound or excipients is possible.
- Symptoms may include skin rash, urticaria, pruritus, facial swelling, wheezing, dizziness, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Antiretroviral combinations may alter exposure through CYP pathways.
- Hepatotoxic medicines or alcohol may increase liver risk.
- CYP3A inhibitors or inducers should be reviewed carefully.
PREAUTIONS–
- Do not use in patients with active liver disease unless specifically justified by protocol.
- Monitor liver enzymes closely in any research use.
- Confirm CCR5-tropic virus if used in an HIV research context.
- Pregnancy safety is not established.
WARNINGS –
- Development was stopped because of safety concerns including hepatotoxicity.
- Serious liver injury is a potential risk.
- Not approved for clinical use.
Share on -
. Developed by